Form 4: Solid Biosciences Director, Martin I Freed, Acquires Stock Options

Director Martin I Freed acquired stock options in Solid Biosciences Inc. on June 11, 2024.

Summary

• On June 11, 2024, Martin I Freed, a director of Solid Biosciences Inc., was granted stock options to purchase 34,400 shares of common stock.
• The exercise price of the options is $7.51 per share.
• The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date.
• The options will also vest automatically as to 100% of the unvested portion upon specified change in control events.
• The options expire on June 11, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, indicating a neutral sentiment.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes the director to remain with the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Stock option grants are a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The granting of stock options can potentially increase shareholder value by aligning management's interests with those of the shareholders.

Key Dates